세계의 여행 백신 시장 규모는 2024년에 44억 달러에 달했습니다. IMARC Group은 2025-2033년의 성장률(CAGR)이 9.36%로, 2033년에는 100억 달러에 달할 것으로 예측하고 있습니다. 이 시장은 이국적이고 인적이 드문 곳의 여행 체험에 대한 수요의 증가, 공중위생 프로그램의 일환으로서 국민에게 무료 여행 예방 접종을 제공하는 정부 구상, 질병 패턴의 변화 및 새로운 위협의 출현 등에 의해 꾸준한 성장을 달성하고 있습니다.
시장 성장 및 규모: 이 시장은 해외 여행 활동 증가로 인해 강력한 성장세를 보이고 있습니다. 또한 여행 관련 질병에 대한 대중의 인식이 높아지면서 시장 성장을 가속하고 있습니다.
기술 발전: 보다 편리하고 효과적인 제형 도입 등 백신 개발의 기술 혁신은 여행자를 보다 확실하게 보호할 수 있습니다.
산업적 용도: 여행용 백신은 다양한 질병에 대한 예방을 제공하므로 레저 및 출장 여행객 모두에게 매우 중요합니다.
지역적 동향 : 북미는 여행 중 건강과 안전에 중점을 두고 있으며, 시장을 선도하고 있습니다. 그러나 다양한 여행지가 있고 해외 여행객이 많은 유럽이 급성장하는 시장으로 부상하고 있습니다.
경쟁 환경: 시장의 주요 기업은 전략적 구상에 적극적으로 참여하고 있습니다. 백신 포트폴리오를 확장하고, 여행과 관련된 새로운 건강 위험에 대응하고, 기존 백신의 효능을 강화하기 위해 연구개발(R&D) 활동에 투자하고 있습니다.
과제와 기회: 백신 접종에 대한 망설임과 규제 장벽과 같은 과제에 직면하고 있는 반면, 백신 접근성 확대와 지역 맞춤형 백신 솔루션과 같은 기회도 있습니다.
미래 전망: 백신 제조 연구개발(R&D)이 진행되고 있으며, 여행용 백신 시장의 미래는 유망합니다. 또한 여행 전 상담에 디지털 헬스 솔루션이 도입되면서 시장 성장이 촉진될 것으로 예상됩니다.
해외여행 증가
전 세계 대중의 해외 여행이 증가하면서 시장 성장을 지원하고 있습니다. 세계화와 여행에 대한 접근성이 높아짐에 따라 전 세계 곳곳에서 감염성 질환에 노출될 위험이 증가하고 있습니다. 여행자들은 의료 수준과 질병 유행이 다른 목적지로 여행을 떠나기 때문에 예방접종은 매우 중요한 예방책이 되고 있습니다. 이러한 추세는 레저 여행, 비즈니스 여행, 해외 유학이 증가함에 따라 더욱 가속화되고 있습니다. 또한 이국적이고 외딴 곳을 여행하고 싶은 욕망으로 인해 개인은 독특한 건강 위험 지역을 탐험하고 특별한 백신의 필요성을 강조하고 있습니다. 여행 중 건강 예방에 대한 개인의 인식이 높아짐에 따라 해외 여행객을 위한 백신의 중요성이 부각되고 있으며, 시장 전망은 긍정적입니다.
정부의 구상과 규제
정부의 구상과 규제는 시장의 견인차로서 매우 중요한 역할을 하고 있습니다. 많은 국가들이 공중 보건을 보호하고 해외 여행으로 인한 질병 확산을 방지하는 것의 중요성을 인식하고 있습니다. 그 결과, 여러 국가의 정부 기관은 여행 예방접종에 대한 엄격한 규제와 권장 사항을 시행하고 있습니다. 이러한 규제는 국경을 출입하는 여행자, 특히 질병 위험이 알려진 여행지로 여행하는 여행자에게 특정 예방접종을 의무화하는 경우가 많습니다. 세계보건기구(WHO)의 국제보건규칙(IHR)은 특정 국가를 방문하는 여행자에게 황열병 예방접종 증명서를 요구하고 있습니다. 또한 일부 정부는 공중보건 프로그램의 일환으로 국민들에게 여행용 예방접종을 보조 또는 무료로 제공합니다. 이러한 규제와 노력은 여행자에게 법적 요건을 부과할 뿐만 아니라 여행용 백신의 필요성에 대한 인식을 높이고 시장 수요를 견인하고 있습니다.
세계 질병 발생과 유행
전 세계적인 질병 유행과 팬데믹은 시장을 촉진하는 큰 영향을 미치고 있습니다. 이러한 사건들은 여행자와 정부에 용기를 주고, 해외 여행에 따른 잠재적인 건강 위험을 강조하고 있습니다. 이러한 전염병에 대응하여 특정 지역에서 유행하는 특정 전염병으로부터 자신을 보호할 수 있는 백신에 대한 수요가 증가하고 있습니다. 질병 유행과 팬데믹은 바이러스 확산을 완화하고 안전한 여행을 촉진하는 백신의 개발 및 배포로 이어지고 있습니다. 여행자들은 자신과 타인을 보호하기 위해 예방접종의 필요성을 더욱 강하게 인식하게 되었고, 이는 여행용 백신의 보급으로 이어지고 있습니다. 각국 정부와 국제보건기구는 전염병 발생을 예방하고 통제하는 중요한 수단으로서 백신의 중요성을 강조하며, 여행자들이 여행 전에 예방접종을 받을 것을 권장하고 있습니다.
질병 패턴의 변화와 새로운 위협
질병 패턴의 역동적인 특성과 새로운 감염 위협의 출현으로 시장 성장이 강화되고 있습니다. 전염병은 정적인 것이 아니라 진화하고 변이하며 새로운 지역으로 퍼져나갑니다. 이러한 시시각각 변화하는 상황 속에서 진화하는 병원체와 싸우기 위한 백신의 지속적인 연구개발(R&D) 활동이 요구되고 있습니다. 지카 바이러스나 에볼라 출혈열과 같은 질병은 최근 여행자들에게 심각한 우려 사항으로 떠오르고 있으며, 이러한 위협에 대응하기 위한 특정 백신 개발을 촉구하고 있습니다. 이러한 질병 패턴의 변화에 대한 인식은 정보 접근의 용이성과 함께 여행 전에 예방접종을 통해 자신을 보호하려는 개인의 행동을 촉진하고 있습니다.
The global travel vaccines market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 10.0 Billion by 2033, exhibiting a growth rate (CAGR) of 9.36% during 2025-2033. The market is experiencing steady growth driven by the escalating demand for exotic and off-the-beaten-path travel experiences, government initiatives to provide free travel vaccinations to their citizens as part of public health programs, and changing disease patterns and emerging threats.
Market Growth and Size: The market is witnessing strong growth, which can be attributed to increasing international travel activities. In addition, the rising awareness among the masses about travel-related diseases is bolstering the market growth.
Technological Advancements: Innovations in vaccine development, such as the introduction of more convenient and effective formulations, is ensuring better protection for travelers.
Industry Applications: Travel vaccines are crucial for both leisure and business travelers, as they offer protection against various diseases.
Geographical Trends: North America leads the market, on account of its strong emphasis on health and safety during travel. However, Europe is emerging as a fast-growing market, driven by its diverse range of destinations and a large number of international travelers.
Competitive Landscape: Key players in the market are actively engaged in strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks, and enhancing existing efficacy of vaccines.
Challenges and Opportunities: While the market faces challenges, such as vaccine hesitancy and regulatory hurdles, it also encounters opportunities in expanding vaccine accessibility and tailored vaccine solutions for specific regions.
Future Outlook: The future of the travel vaccines market looks promising, with ongoing research and development (R&D) activities in vaccine production. Moreover, the adoption of digital health solutions for pre-travel consultations is expected to propel the growth of the market.
Rising international travel
The increasing international travel among the masses around the world is supporting the growth of the market. As globalization and accessibility to travel are growing, the risk of exposure to infectious diseases in various parts of the world is rising. Travelers are venturing to destinations with varying healthcare standards and disease prevalence, making vaccinations a crucial precaution. This trend is further bolstered by the growth of leisure travel, business travel, and international students studying abroad. Moreover, the desire for exotic and off-the-beaten-path travel experiences is leading individuals to explore regions with unique health risks, emphasizing the need for specialized vaccines. The growing awareness among individuals about health precautions while traveling is underscoring the importance of vaccines for international travelers, which is offering a favorable market outlook.
Government initiatives and regulations
Government initiatives and regulations play a pivotal role in driving the market. Many countries are recognizing the importance of safeguarding public health and preventing the spread of diseases through international travel. As a result, governing agencies of several countries are implementing stringent regulations and recommendations regarding travel vaccinations. These regulations often mandate certain vaccinations for travelers entering or exiting their borders, especially for destinations with known disease risks. The International Health Regulations (IHR) by the World Health Organization (WHO) require proof of yellow fever vaccination for travelers visiting certain countries. Additionally, some governments offer subsidized or free travel vaccinations to their citizens as part of public health programs. These regulations and initiatives not only create a legal requirement for travelers but also raise awareness about the necessity of travel vaccines, driving demand in the market.
Global disease outbreaks and pandemics
Global disease outbreaks and pandemics have a profound impact on driving the market. These events are encouraging travelers and governments, highlighting the potential health risks associated with international travel. In response to such outbreaks, there is an escalating demand for vaccines that can protect against specific infectious diseases prevalent in certain regions. Disease outbreaks and pandemics are leading to the development and distribution of vaccines to mitigate the spread of the virus and facilitate safe travel. Travelers are becoming more conscious about the need for vaccinations to protect themselves and others, leading to greater adoption of travel vaccines. Governments and international health organizations also emphasize the importance of vaccines as a key tool in preventing and controlling outbreaks, encouraging travelers to be vaccinated before embarking on their journeys.
Changing disease patterns and emerging threats
The dynamic nature of disease patterns and the emergence of new infectious threats are strengthening the growth of the market. Infectious diseases are not static, they evolve, mutate, and spread to new regions. This ever-changing landscape necessitates ongoing research and development (R&D) activities of vaccines to combat evolving pathogens. Diseases like Zika virus and Ebola are emerging as significant concerns for travelers in recent years, prompting the development of specific vaccines to address these threats. This awareness of changing disease patterns, along with the ease of accessing information, is encouraging individuals to seek protection through vaccinations before embarking on their journeys.
Mono Vaccines
Combination Vaccines
Combination vaccines account for the majority of the market share
Combination vaccines offer the convenience of protecting against multiple diseases with a single injection. Popular combination vaccines include those that guard against hepatitis A and B, as well as typhoid. The primary advantage of combination vaccines is their efficiency in providing comprehensive protection, simplifying the vaccination process for travelers. This convenience is especially appealing to individuals who plan to visit regions with multiple disease risks, reducing the number of shots required. The combination vaccines segment is growing due to increased demand for streamlined vaccination regimens and improved compliance among travelers seeking a one-shot solution for their health needs.
Mono vaccines consist of individual vaccines targeting specific diseases. These vaccines are designed to provide protection against a single infectious agent, such as hepatitis A, hepatitis B, or typhoid. Mono vaccines are often recommended when travelers are visiting regions with a particularly high risk of one specific disease. They offer the advantage of targeted protection, allowing travelers to customize their vaccination regimen based on their destination and individual health needs.
Hepatitis A
DPT
Yellow Fever
Typhoid
Hepatitis B
Measles and Mumps
Rabies
Meningococcal
Varicella
Japanese Encephalitis
Others
Hepatitis A represents the leading market segment
Hepatitis A is a highly contagious viral infection that can be contracted through contaminated food or water, making it a significant concern for travelers. This segment includes vaccines that provide immunity against the hepatitis A virus. Due to its prevalence in many travel destinations, hepatitis A vaccination is recommended for individuals traveling to regions with inadequate sanitation and hygiene standards. The prominence of hepatitis A in the market reflects the widespread recognition of its risk and the importance of vaccination for the health and safety of travelers.
DPT vaccines, which protect against diphtheria, pertussis (whooping cough), and tetanus, are another important segment in the travel vaccines market. While these diseases are not exclusive to travel-related risks, they are included in some international vaccination recommendations. Tetanus can be a concern if travelers are exposed to contaminated wounds during their journeys. Therefore, DPT vaccines are essential for ensuring comprehensive protection against these preventable diseases, even when traveling.
Yellow fever vaccines target the prevention of yellow fever, a mosquito-borne viral disease prevalent in certain tropical regions. Travelers visiting countries in Africa and South America where yellow fever is endemic often require proof of vaccination for entry. The yellow fever segment in the travel vaccines market serves travelers who plan to explore these high-risk areas and need to adhere to international health regulations.
Typhoid vaccines are essential for travelers heading to regions with a higher risk of typhoid fever, often linked to contaminated food and water sources. These vaccines protect against Salmonella typhi, the bacterium responsible for typhoid fever. The typhoid segment addresses the specific health needs of travelers venturing to areas with suboptimal sanitation and hygiene conditions.
Hepatitis B vaccines are important for travelers who may engage in activities that carry an elevated risk of exposure to the hepatitis B virus, such as unprotected sexual contact or medical procedures involving needles. While hepatitis B is not exclusive to travel, these vaccines cater to the needs of individuals seeking protection against this virus while away from their home country.
Asia Pacific
North America
Europe
Middle East and Africa
Latin America
North America leads the market, accounting for the largest travel vaccines market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. According to the report, North America accounted for the largest market share due to the high level of outbound international travel from the United States and Canada. The region has a strong emphasis on health and safety during travel, and travelers are well-informed about the importance of vaccinations. Additionally, government recommendations and regulations, including those set by the Centers for Disease Control and Prevention (CDC) in the United States, play a significant role in promoting the uptake of travel vaccines. North America also benefits from a well-established healthcare infrastructure and a robust pharmaceutical industry, making travel vaccines readily accessible to the population.
Europe is another substantial market for travel vaccines. With its diverse range of destinations and a large number of international travelers, European countries have a strong demand for travel vaccinations. The European Union is establishing guidelines for travelers, recommending vaccinations based on destination and health history. European travelers tend to be proactive in seeking pre-travel healthcare advice, contributing to the growth of the market in the region.
The Asia Pacific region is experiencing rapid growth in the market due to a rise in outbound tourism and business travel. As economies in the region are expanding, more individuals have the means and desire to explore international destinations. This is resulting in a heightened awareness of travel-related health risks, catalyzing the demand for travel vaccines. Moreover, some countries are becoming popular tourist destinations, leading to an increase in inbound travelers who also require vaccinations.
The Middle East and Africa region also contribute to the market. This segment is driven by both outbound tourism and inbound travelers, as the region hosts various cultural, religious, and business events. Vaccinations are often mandated for individuals traveling to Mecca for Hajj or Umrah, further propelling the market growth. In addition, the presence of diseases like yellow fever and malaria underscores the importance of vaccinations for travelers.
Latin America is another growing market for travel vaccines, driven by increasing outbound travel from countries like Brazil and Mexico. Travelers from these regions often explore destinations within South America, North America, and Europe, necessitating vaccinations for disease prevention.
Key players in the market are actively engaged in several strategic initiatives. They are investing in research and development (R&D) activities to expand their vaccine portfolios, addressing emerging travel-related health risks and enhancing existing efficacy of vaccines. These companies are also focusing on increasing their global distribution networks to ensure accessibility to travel vaccines in diverse regions. Furthermore, they collaborate with healthcare providers, government agencies, and international health organizations to promote vaccination awareness and education among travelers. Additionally, pharmaceutical firms are exploring innovative vaccine delivery methods, such as oral or patch-based vaccines, to improve convenience and compliance for travelers. Overall, key players are dedicated to advancing the field of travel vaccines to meet the evolving needs of global travelers effectively.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:
GlaxoSmithKline Pharmaceuticals Limited
Sanofi Pasteur
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
ALK-Abello A/S
Bavarian Nordic A/S
Crucell (Subsidiary of Johnson & Johnson)
CSL Limited
AstraZeneca PLC
Altimmune, Inc.
Abbott Laboratories
Hoffmann-La Roche, Inc.